Page last updated: 2024-09-05

esketamine and Depressive Disorder, Treatment-Resistant

esketamine has been researched along with Depressive Disorder, Treatment-Resistant in 150 studies

Research

Studies (150)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	18 (12.00)	24.3611
2020's	132 (88.00)	2.80

Authors

Authors	Studies
Buoli, M; Caldiroli, A; Capellazzi, M; Capuzzi, E; Clerici, M; Colmegna, F; Dakanalis, A; Marcatili, M; Tagliabue, I	1
Goto, R; Shimizu, H; Shiraishi, A; Takahashi, N; Tominaga, Y; Yamada, A	1
de la Vega Sánchez, D; López-Díaz, Á; Rendón de Lope, L	1
Audi, EA; Batistela, MF; Frias, AT; Graeff, FG; Hernandes, PM; Joca, SRL; Maraschin, JC; Martinez, LM; Spera de Andrade, TGC; Zangrossi, H	1
Bentivoglio, AR; Calabresi, P; Camardese, G; Di Nicola, M; Janiri, D; Lanzotti, P; Moccia, L; Palumbo, L; Pepe, M; Sani, G	1
Reus, VI	1
Schatzberg, AF	2
McIntyre, RS	1
Bandeira, ID; Beanes, G; Caliman-Fontes, AT; Cardoso, TA; Carvalho, LP; Carvalho, MS; Correia-Melo, FS; Echegaray, M; Jesus-Nunes, AP; Kapczinski, F; Lacerda, ALT; Leal, GC; Machado, P; Magnavita, G; Mello, RP; Paixão, CS; Quarantini, LC; Sampaio, AS; Silva, SS; Vieira, F	1
Baudot, J; Mezaache, S; Micallef, J; Navarro, N; Soeiro, T; Tambon, M; Veyrac, G	1
Han, X; Lei, C; Li, Y; Liu, H; Tao, Z; Yang, Y; Yuan, X; Zhang, K; Zhang, W	1
Canuso, CM; Cooper, K; Daly, EJ; Freeman, MP; Jones, RR; Kornstein, SG; Nicholson, S	1
Dalla, C; Kokras, N; Megalokonomou, A; Pavlidi, P; Sofron, A	1
Cestac, P; Jullien, A; Montastruc, F; Taillefer de Laportalière, T; Yrondi, A	1
Chen, G; Chen, L; Daly, EJ; Drevets, WC; Fedgchin, M; Furey, ML; Lane, R; Li, X; Lim, P; Popova, V; Singh, JB; Zhang, Y	1
Horowitz, M; Moncrieff, J	1
Kasper, S; Lanzenberger, R; Naderi-Heiden, A; Praschak-Rieder, N; Unterholzner, J; Vanicek, T	1
Curran, HV; Freeman, TP; Grabski, M; van Laar, M; Waldron, J	1
Aloysi, A; Evers, A; Jha, MK; Klein, M; Murrough, J	1
Bouju, S; Codet, MA; Gaudré-Wattinne, E; Mekaoui, L; Rothärmel, M; Samalin, L; Sauvaget, A	1
Bandeira, ID; Caliman-Fontes, AT; Correia-Melo, FS; Echegaray, MVF; Guerreiro-Costa, LNF; Jesus-Nunes, AP; Kapczinski, F; Lacerda, ALT; Leal, GC; Marback, RF; Mello, RP; Quarantini, LC; Santos-Lima, C; Souza, LS; Souza-Marques, B; Vieira, F	1
Alnafeesi, Y; Ceban, F; Di Vincenzo, JD; Gillissie, ES; Jaberi, S; Jawad, MY; Lui, LMW; McIntyre, RS; Rosenblat, JD	1
Krystal, JH; Murphy, E; Nikayin, S; Wilkinson, ST	1
Kritzer, MD; Masand, PS; Pae, CU	1
Rosenman, S	1
Cunningham, ME; de Fontnouvelle, CA; Nikayin, S; Ostroff, RB; Rhee, TG; Sanacora, G; Wilkinson, ST	1
Aan Het Rot, M; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Veraart, JK; Vischjager, M	1
Kobayashi, H; Ohnishi, T; Wakamatsu, A	1
Borentain, S; Cabrera, P; Carmody, T; Daly, EJ; DiBernardo, A; Gogate, J; Jamieson, C; Popova, V; Trivedi, M; Wajs, E; Williamson, D	1
Achtyes, ED; Farber, NB; Frye, MA; Goes, FS; Gould, TD; Grunebaum, MF; Machado-Vieira, R; Medeiros, GC; Nanavati, J; Parikh, SV; Prueitt, WL; Selvaraj, S; Singh, B; Zarate, CA	1
Cook, J; Halaris, A	1
Javed, S; Kotra, M; Malathesh, BC; Nguyen, VS; Shoib, S	1
Abdo, GL; Barbosa, MG; de Oliveira Cerqueira, R; Del Porto, JA; Del Sant, LC; Delfino, RS; Fava, VAR; Grossi, JD; Lacerda, ALT; Lucchese, AC; Magalhães, E; Nakahira, C; Sarin, LM; Steglich, MS; Surjan, J; Tuena, MA	1
Ceban, F; Di Vincenzo, JD; Ho, C; Lee, Y; Levinta, A; Lui, LMW; Mansur, RB; McIntyre, RS; Meshkat, S; Rodrigues, NB; Rosenblat, JD; Teopiz, KM	1
Daly, EJ; Gogate, JP; Kern Sliwa, JK; Manera, LS; Preskorn, SH; Starr, HL; Williamson, DJ; Winokur, A	1
Andriola, I; Barlati, S; Bassetti, R; Belletti, S; Bellomo, A; Bertolino, A; Chiaie, RD; Clerici, M; Conca, A; d'Andrea, G; De Fazio, P; De Filippis, S; Dell'Osso, B; di Giannantonio, M; Di Lorenzo, G; Di Mauro, S; Di Nicola, M; Fagiolini, A; Maina, G; Martiadis, V; Martinotti, G; McIntyre, RS; Nicolò, G; Nucifora, D; Olivola, M; Pettorruso, M; Rosso, G; Sani, G; Siracusano, A; Valchera, A; Vita, A	1
Gutiérrez, G; Vázquez, G	1
Dycha, N; Kurzepa, J; Nowak, EM; Psiuk, D; Samardakiewicz, M; Łopuszańska, U	1
Huang, X; Tao, Y; Xu, H	1
Daly, EJ; Jha, MK; Magharehabed, G; Trivedi, MH; Turkoz, I; Williamson, DJ	1
Kamphuis, J; Kutscher, M; Meij, AV; Schoevers, RA; Smith-Apeldoorn, SY; Veraart, JKE; Vischjager, M	1
Badulescu, S; Ceban, F; Di Vincenzo, JD; Ho, RC; Jawad, MY; McIntyre, RS; Mckenzie, A; Meshkat, S; Rosenblat, JD; Tabassum, A; Teopiz, KM	1
Borentain, S; Drevets, WC; Singh, JB; Turkoz, I; Wajs, E; Williamson, D	1
Bahji, A; Vazquez, GH; Zarate, CA	2
Do, A; Giacobbe, P; Gutierrez, G; Hawken, E; Karthikeyan, G; Lam, RW; Milev, R; Ravindran, N; Rosenblat, J; Schaffer, A; Swainson, J; Vazquez, G	1
Comparelli, A; Erbuto, D; Manfredi, G; Pompili, M; Sarli, G	1
Andriola, I; Barlati, S; Bassetti, R; Bertolino, A; Cavallotto, C; Chiappini, S; Clerici, M; d'Andrea, G; De Fazio, P; De Filippis, S; Dell'Osso, B; di Giannantonio, M; Di Lorenzo, G; Di Mauro, S; Di Nicola, M; Maina, G; Marcatili, M; Martinotti, G; McIntyre, RS; Nicolò, G; Nucifora, D; Pettorruso, M; Rosso, G; Sensi, SL; Vita, A; Zanardi, R	1
Eloge, JC; Mackey, IV; Wallner, MA; Zajecka, J	1
Garcia-Romeu, A; Mathai, DS; Nayak, SM; Yaden, DB	1
Lugg, W	1
d'Andrea, G; Lorenzo, GD; Mancusi, G; Martinotti, G; McIntyre, RS; Pettorruso, M	1
Borentain, S; Daly, E; Macaluso, M; Nelson, JC; Salvadore, G; Sheehan, JJ; Singh, J; Trivedi, MH; Turkoz, I; Wilkinson, ST; Williamson, D	1
Andriola, I; Barlati, S; Bassetti, R; Chiappini, S; Clerici, M; d'Andrea, G; De Filippis, S; Dell'Osso, B; Di Nicola, M; Martinotti, G; Pettorruso, M; Sensi, S; Vita, A	1
Feeney, A; Papakostas, GI	1
Gebara, MA; Lenze, EJ; Oughli, HA; Palanca, BJA; Subramanian, S	1
Chen, LN; Doherty, T; Drevets, WC; Fu, DJ; Lane, R; Morrison, RL; Popova, V; Sanacora, G; Wilkinson, ST; Zaki, N	1
Breeksema, JJ; Kamphuis, J; Kuin, B; Niemeijer, A; Schoevers, R; van den Brink, W; Veraart, J; Vermetten, E	1
Araújo, GAC; Bisol, LW; Gomes de Matos E Souza, F; Gonçalves, MAS; Júnior, EAB; Leite, TRA	1
Bartolucci, G; Camardese, G; Di Nicola, M; Marcelli, I; Pepe, M; Sani, G; Simonetti, A	1
Caron-Lapointe, G; Joshi, K; Lefebvre, P; Pilon, D; Teeple, A; Zhdanava, M	1
Al Jurdi, RK; Borentain, S; Brown, B; Cabrera, P; Castro, M; Fu, DJ; Petrillo, MP; Sun, L; Turkoz, I; Wilkinson, ST; Zaki, N	1
Andriola, I; Barlati, S; Bassetti, R; Carullo, R; Chiappini, S; Clerici, M; D'Andrea, A; d'Andrea, G; De Fazio, P; De Filippis, S; De Risio, L; Di Lorenzo, G; Di Nicola, M; Guidotti, R; Marcatili, M; Maria Dell'Osso, B; Martiadis, V; Martinotti, G; Marzetti, L; McIntyre, RS; Nicolò, G; Nucifora, D; Pettorruso, M; Rosenblat, JD; Rosso, G; Sensi, SL; Vita, A; Zanardi, R	1
Cohen, D; Curiale, V; Jacquet, B; Laurent, I; Louchart De La Chapelle, S; Romani, S	1
d'Andrea, G; Di Lorenzo, G; Martinotti, G; McIntyre, RS; Pettorruso, M; Rhee, TG	1
Advenier-Iakovlev, E; Danon, M; De Maricourt, P; Estrade, I; Gaillard, R; Gorwood, P; Leroy, S; Mancusi, RL; Mekaoui, L; Perrain, R; Petit, AC; Poupon, D; Sylvestre, V; Vinckier, F	1
Fu, DJ; Hong, JP; Ju, PC; Li, CT; Madriaga, G; Malek, AZA; Paik, JW; Siggins, S; Sulaiman, AH; Zhuo, J	1
Bitter, I; Buyze, J; Cebulla, K; Frey, R; Fu, DJ; Godinov, Y; Ito, T; Kambarov, Y; Llorca, PM; Messer, T; Mulhern-Haughey, S; Oliveira-Maia, AJ; Reif, A; Rive, B; von Holt, C; Young, AH	1
Harris, E	1
Black, W; Bognar, A; Callander, JS; Dagge, D; Gitau, T; Hua, B; Joks, G; King, J; Liu, D; Lord, A; Scott, EM; Thornton, NLR; Ting, S	1
Endo, K; Kodama, W; Terao, I; Tsuge, T	1
Daly, EJ; Drevets, WC; Hough, D; Manji, H; Popova, V; Singh, JB	1
Kawalec, P; Kryst, J; Pilc, A	1
Cristea, IA; Naudet, F	2
Turner, EH	2
Lavretsky, H; Roose, SP	1
Adler, C; Daly, EJ; Drevets, WC; Gaillard, R; Hough, D; Lane, R; Lim, P; Manji, H; McShane, R; Morrison, RL; Ochs-Ross, R; Sanacora, G; Singh, JB; Steffens, DC; Wilkinson, ST; Zhang, Y	1
Chakrabarti, SS; Kaur, U; Pathak, BK; Singh, A	1
Bitter, I; Bolyós, C; Czobor, P; Nagy, M; Réthelyi, J	1
Aan Het Rot, M; Kamphuis, J; Schoevers, RA; Smith-Apeldoorn, SY; Touw, DJ; van Asselt, ADI; Veraart, JKE	1
Araújo-de-Freitas, L; Bandeira, ID; Caliman-Fontes, AT; Cavalcanti, DE; Correia-Melo, FS; Del-Porto, JA; Echegaray, MVF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Loo, C; Magnavita, G; Mello, RP; Nakahira, C; Quarantini, LC; Sampaio, AS; Sarin, LM; Silva, SS; Tuena, MA; Turecki, G; Vieira, F	1
Bozymski, KM; Crouse, EL; Kirkwood, CK; Nofziger, JL; Ott, CA; Titus-Lay, EN	1
Barbui, C; Gastaldon, C; Ostuzzi, G; Papola, D	2
Agboola, F; Atlas, SJ; Fazioli, K; Pearson, SD; Touchette, DR	1
Dadiomov, D	1
Baker, KD; Richardson, R; Zimmermann, KS	1
Doherty, T; Melkote, R; Miller, J; Singh, JB; Wajs, E; Weber, MA	1
Bolaños-Guzmán, CA; Gnecco, T; Parise, EM; Parise, LF; Sial, OK	1
Chang, L; Hashimoto, K; Wei, Y	1
Daly, EJ; Drevets, WC; Fedgchin, M; Hough, D; Mathews, M; Popova, V; Singh, JB	1
Jalloh, M	1
Charney, DS; Duman, RS; Krystal, JH	1
Aluisio, L; Borentain, S; Daly, E; DiBernardo, A; Janik, A; Nijs, M; Singh, JB; Turkoz, I; Wajs, E; Wiegand, F	1
Aluisio, L; Daly, EJ; Drevets, WC; George, JE; Grunfeld, J; Holder, R; Hough, D; Jeon, HJ; Kasper, S; Lane, R; Li, CT; Lim, P; Manji, H; Morrison, RL; Paik, JW; Sanacora, G; Singh, JB; Sulaiman, AH; Wajs, E; Wilkinson, ST; Young, AH	1
Canuso, C; Daly, EJ; Drevets, WC; Heerlein, K; Mathews, M; Popova, V	1
Chen, G; Drevets, WC; Fedgchin, M; Furey, ML; Hibar, D; Kolb, H; Popova, V; Saad, Z; Singh, JB	1
Fantasia, HC	1
David, S	1
Horowitz, MA; Moncrieff, J	1
Fava, M; Hock, RS; Iosifescu, DV; Jha, MK; Mathew, SJ; Murrough, JW; Papakostas, GI; Salloum, NC	1
Borissova, A; Curran, HV; Grabski, M; Marsh, B; Morgan, CJA	1
Bartova, L; Dold, M; Kasper, S	1
Kolar, D	1
Abdo, G; Barbosa, M; Cohrs, FM; de Jesus Mari, J; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VAR; Lacerda, ALT; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA	1
Burns, T; Gills, T; Moomaw, S; Osburn, S; Pawlowska-Wajswol, S; Stanley, N; Stultz, DJ; Walton, R	1
Ning, YP; Sim, K; Xiang, YT; Zheng, W	1
Khorassani, F; Talreja, O	1
Abell, J; Daly, E; DeMuro, C; Gogate, J; Jamieson, C; Kramer, M; Larish, A; Lewis, S; Starr, HL; Zaki, N	1
Doherty, T; Hough, D; Katz, EG; Lane, R; Levitan, B; Singh, J	1
Cubała, WJ; Fagiolini, A; Kasper, S; Ramos-Quiroga, JA; Souery, D; Young, AH	1
Blackowicz, M; Cooper, K; Drevets, WC; Fedgchin, M; Floden, L; Hudgens, S; Jamieson, C; Lane, R; Popova, V; Singh, J	1
Bressan, RA; Lacerda, ALT; Machado, C; Noto, C	1
Baune, BT; Hassan, A; Kavakbasi, E	1
Abdo, G; B Andreoli, S; B Puertas, C; Barbosa, M; Cohrs, FM; Del Porto, JA; Del Sant, LC; Delfino, R; Fava, VA; Lacerda, AL; Liberatori, A; Lucchese, AC; Magalhães, EJM; Nakahira, C; Sarin, LM; Steiglich, MS; Surjan, J; Tuena, MA	1
Elowe, J; Khazaal, Y; Kloucek, P; Preisig, M; Ros, T; Tadri, M; Vandeleur, C; Vandenberghe, F; Verloo, H; Von Guntenb, A	1
Canuso, CM; Cepeda, MS; Kern, DM	1
Cao, B; Cha, DS; Gill, H; Ho, R; Kratiuk, K; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Ng, J; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM; Xiong, J	1
Kamphuis, J; Schlegel, M; Schoevers, RA; Veraart, JKE	1
Borentain, S; Canuso, CM; Cepeda, MS; Daly, EJ; Drevets, WC; Lane, R; Manji, HK; Mathews, M; Popova, V	1
Correia-Melo, FS; Jesus-Nunes, AP; Mello, RP; Quarantini, LC; Sampaio, AS; Souza-Marques, B	1
Brula, AQ; Sanders, B	1
Berk, M; Brietzke, E; Dodd, S; Gorwood, P; Ho, R; Iosifescu, DV; Kasper, S; Kratiuk, K; Lee, JG; Lee, Y; Lopez Jaramillo, C; Lui, LMW; Mansur, RB; McIntyre, RS; Murrough, JW; Nemeroff, CB; Papakostas, GI; Rosenblat, JD; Sanacora, G; Stahl, S; Subramaniapillai, M; Thase, M; Vieta, E; Young, AH; Zarate, CA	1
Ekstrand, J	1
Bandeira, ID; Caliman-Fontes, AT; Correia-Melo, FS; Echegaray, MVF; Guerreiro-Costa, LNF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Magnavita, GM; Marback, RF; Mello, RP; Quarantini, LC; Santos-Lima, C; Souza-Marques, B; Telles, M; Vieira, F	1
Abreu, N; Araújo-de-Freitas, L; Beanes, G; Cardoso, TL; Correia-Melo, FS; Echegaray, MV; França, RJAF; Guerreiro-Costa, LNF; Jesus-Nunes, AP; Lacerda, ALT; Leal, GC; Lucchese, AC; Magnavita, G; Marback, R; Mello, RP; Mendonça-Filho, E; Quarantini, LC; Rabanea, T; Santos-Lima, C; Souza-Marques, B; Teles, M; Vieira, F	1
Marom, A; Rosca, P	1
Cao, B; Cha, DS; Gill, H; Ho, RC; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Ng, J; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM	1
Cooper, K; Daly, E; Doty, RL; Drevets, WC; Fedgchin, M; Jamieson, C; Janik, A; Lane, R; Lim, P; Melkote, R; Ochs-Ross, R; Popova, V; Singh, J; Wylie, C	1
Bahji, A; Baldessarini, RJ; Tondo, L; Undurraga, J; Vázquez, GH	1
Bauer, M; Findeis, H; Ludwig, VM; Ritter, P; Rucker, J; Sauer, C; Young, AH	1
Borentain, S; Daly, EJ; Fedgchin, M; Ionescu, DF; Salvadore, G; Singh, JB; Starr, HL; Thase, ME; Trivedi, MH; Turkoz, I	1
Bisol, LW; da Costa, JPOM; Souza, FGME	2
Cooper, K; Daly, EJ; Drevets, WC; Fedgchin, M; Lim, P; Manji, H; Shelton, RC; Singh, JB; Thase, ME; Van Nueten, L; Winokur, A	1
Cooper, K; Daly, E; Fedgchin, M; Singh, JB; Targum, SD	1
Chang, L; Dong, C; Fujita, Y; Hashimoto, K; Pu, Y; Qu, Y; Ren, Q; Wang, SM; Xiong, Z; Zhang, K	1
Bajbouj, M; Cooper, K; Daly, EJ; Drevets, WC; Hough, D; Lane, R; Lim, P; Manji, H; Mazzucco, C; Molero, P; Popova, V; Shelton, RC; Singh, JB; Thase, ME; Trivedi, M; Vieta, E	1
Bitter, I; Blier, P; Cubala, WJ; Daly, EJ; Divacka, I; Drevets, WC; Duca, AR; Fagiolini, A; Hough, D; Janik, A; Lane, R; Li, H; Li, X; Lim, P; Manji, H; Molero, P; Shelton, RC; Singh, JB; Thase, ME; Trivedi, MH; Winokur, A; Zajecka, J; Zhang, Y	1
Elfving, B; Harvey, BH; Joca, SRL; Pereira, VS; Wegener, G	1
Aschenbrenner, DS	1
Fonseca-Perezamador, A; García-Mendoza, AM; Kobayashi-Romero, LF; Lamas-Aguilar, RM; Pérez-Esparza, R	1
Archer, S; Baker, G; Chokka, P; Chrenek, C; Demas, ML; Dursun, S; Klassen, LJ; MacKay, MA; Swainson, J; Thomas, RK	1
Ameele, HVD; Blier, P; Daly, EJ; Drevets, WC; Fava, M; Fedgchin, M; Gaillard, R; Hough, D; Lane, R; Liebowitz, M; Lim, P; Manji, H; Melkote, R; Preskorn, S; Ravindran, A; Singh, JB; Trivedi, M; Vitagliano, D	1

Reviews

38 review(s) available for esketamine and Depressive Disorder, Treatment-Resistant

Article	Year
Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review. International journal of molecular sciences, 2021, Aug-28, Volume: 22, Issue:17 Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Secondary Prevention	2021
[Pharmacology of ketamine and esketamine as rapid-acting antidepressants]. Psychiatrike = Psychiatriki, 2021, Volume: 32, Issue:Supplement Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Male	2021
The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis. Expert opinion on drug safety, 2022, Volume: 21, Issue:6 Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2022
Long-term safety of ketamine and esketamine in treatment of depression. Expert opinion on drug safety, 2022, Volume: 21, Issue:6 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2022
Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability. Expert opinion on drug safety, 2022, Volume: 21, Issue:6 Topics: Administration, Intranasal; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Randomized Controlled Trials as Topic	2022
The antidepressant effect and safety of non-intranasal esketamine: A systematic review. Journal of psychopharmacology (Oxford, England), 2022, Volume: 36, Issue:5 Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2022
Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis. Molecular psychiatry, 2022, Volume: 27, Issue:9 Topics: Antidepressive Agents; Biomarkers; Brain-Derived Neurotrophic Factor; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2022
Esketamine-A quick-acting novel antidepressant without the disadvantages of ketamine. Hormone molecular biology and clinical investigation, 2022, Dec-01, Volume: 43, Issue:4 Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2022
The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review. Journal of affective disorders, 2022, 12-01, Volume: 318 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2022
Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. International journal of molecular sciences, 2022, Sep-28, Volume: 23, Issue:19 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Ketamine; Psilocybin	2022
Letter to the editor about "Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis". Journal of affective disorders, 2023, 02-01, Volume: 322 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2023
Safety of Ketamine Augmentation to Monoamine Oxidase Inhibitors in Treatment-Resistant Depression: A Systematic Literature Review and Case Series. The Journal of clinical psychiatry, 2022, 10-24, Volume: 83, Issue:6 Topics: Depression; Depressive Disorder, Treatment-Resistant; Drug-Related Side Effects and Adverse Reactions; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Serotonin Syndrome	2022
The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression. Neuropharmacology, 2023, Feb-01, Volume: 223 Topics: Anhedonia; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Psychopathology	2023
Response to "Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis." Journal of affective disorders, 2023, 03-01, Volume: 324 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2023
Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties? European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2023, Volume: 70 Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2023
Pharmacotherapy: Ketamine and Esketamine. The Psychiatric clinics of North America, 2023, Volume: 46, Issue:2 Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2023
Treatment-Resistant Late-Life Depression: A Review of Clinical Features, Neuropsychology, Neurobiology, and Treatment. The Psychiatric clinics of North America, 2023, Volume: 46, Issue:2 Topics: Aged; Alzheimer Disease; Anxiety; Depressive Disorder, Treatment-Resistant; Diagnosis, Differential; Electroconvulsive Therapy; Female; Humans; Inflammation; Ketamine; Neuropsychology; Sleep Initiation and Maintenance Disorders; Transcranial Magnetic Stimulation; Vagus Nerve Stimulation	2023
Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis Journal of affective disorders, 2024, Feb-01, Volume: 346 Topics: Adult; Antidepressive Agents; Aripiprazole; Depression; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Lithium; Network Meta-Analysis	2024
Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:1 Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2020
Esketamine: a glimmer of hope in treatment-resistant depression. European archives of psychiatry and clinical neuroscience, 2021, Volume: 271, Issue:3 Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate	2021
Esketamine: A Novel Option for Treatment-Resistant Depression. The Annals of pharmacotherapy, 2020, Volume: 54, Issue:6 Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Blood Pressure; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ketamine; United States; United States Food and Drug Administration	2020
Ketamine: The final frontier or another depressing end? Behavioural brain research, 2020, 04-06, Volume: 383 Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dopamine Plasma Membrane Transport Proteins; Excitatory Amino Acid Antagonists; Humans; Ketamine; Norepinephrine Plasma Membrane Transport Proteins; Receptor, Muscarinic M1; Receptors, AMPA; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Receptors, Serotonin, 5-HT3; Receptors, sigma; Serotonin Plasma Membrane Transport Proteins	2020
A historical review of antidepressant effects of ketamine and its enantiomers. Pharmacology, biochemistry, and behavior, 2020, Volume: 190 Topics: Animals; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Stereoisomerism; Treatment Outcome	2020
Esketamine (Spravato) for Treatment-Resistant Depression. American family physician, 2020, 03-15, Volume: 101, Issue:6 Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Treatment Outcome	2020
Are we repeating mistakes of the past? A review of the evidence for esketamine. The British journal of psychiatry : the journal of mental science, 2021, Volume: 219, Issue:5 Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Suicide	2021
Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. The Journal of clinical psychiatry, 2020, 05-26, Volume: 81, Issue:4 Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Humans; Ketamine; Treatment Outcome	2020
Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review. Behavioural brain research, 2020, 08-17, Volume: 392 Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Male; Mental Disorders; Mental Health; Middle Aged; Psychotropic Drugs; Substance-Related Disorders; Treatment Outcome	2020
Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment. The international journal of neuropsychopharmacology, 2020, 07-29, Volume: 23, Issue:7 Topics: Administration, Intranasal; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Humans; Ketamine; Nasal Sprays; Randomized Controlled Trials as Topic; Treatment Outcome	2020
Intranasal esketamine: A novel drug for treatment-resistant depression. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2020, 08-20, Volume: 77, Issue:17 Topics: Administration, Intranasal; Administration, Oral; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Humans; Ketamine; Severity of Illness Index	2020
Esketamine for treatment-resistant depression. Drug and therapeutics bulletin, 2020, Volume: 58, Issue:12 Topics: Adult; Aged; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Humans; Ketamine; Middle Aged	2020
[Psychiatry]. Revue medicale suisse, 2021, Jan-13, Volume: 17, Issue:720-1 Topics: COVID-19; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Neurofeedback; Pandemics; Psychiatry; Telemedicine	2021
Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment. Psychopharmacology, 2021, Volume: 238, Issue:4 Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood Disorders	2021
Intranasal esketamine: From origins to future implications in treatment-resistant depression. Journal of psychiatric research, 2021, Volume: 137 Topics: Administration, Intranasal; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2021
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. The American journal of psychiatry, 2021, 05-01, Volume: 178, Issue:5 Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dissociative Disorders; Excitatory Amino Acid Antagonists; Humans; Hypertension; Implementation Science; Ketamine; Lower Urinary Tract Symptoms; Monitoring, Physiologic; Patient Selection; Personnel Staffing and Scheduling; Psychoses, Substance-Induced; Substance-Related Disorders; Suicidal Ideation	2021
[ESKETAMINE FOR TREATMENT RESISTANT DEPRESSION: RESEARCH AND RISK MANAGEMENT]. Harefuah, 2021, Volume: 160, Issue:6 Topics: Administration, Intranasal; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Risk Management	2021
Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. Journal of affective disorders, 2021, 10-01, Volume: 293 Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2021
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. Journal of psychopharmacology (Oxford, England), 2021, Volume: 35, Issue:8 Topics: Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Ketamine; Lithium Compounds; Randomized Controlled Trials as Topic	2021
Esketamine for treatment resistant depression. Expert review of neurotherapeutics, 2019, Volume: 19, Issue:10 Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2019

Trials

28 trial(s) available for esketamine and Depressive Disorder, Treatment-Resistant

Article	Year
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. BMC psychiatry, 2021, 10-25, Volume: 21, Issue:1 Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Japan; Ketamine; Prospective Studies; Treatment Outcome	2021
Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial. Trends in psychiatry and psychotherapy, 2023, Mar-07, Volume: 45 Topics: Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2023
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials. Archives of women's mental health, 2022, Volume: 25, Issue:2 Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Nasal Sprays; Treatment Outcome	2022
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression. Human psychopharmacology, 2022, Volume: 37, Issue:4 Topics: Adult; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Ketamine; Male; Middle Aged; Treatment Outcome	2022
Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression. Psychiatry and clinical neurosciences, 2022, Volume: 76, Issue:8 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Factor Analysis, Statistical; Humans; Ketamine; Placebo Effect; Treatment Outcome	2022
Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine. International journal of methods in psychiatric research, 2022, Volume: 31, Issue:4 Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine; Nasal Sprays; Treatment Outcome	2022
Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability. Journal of affective disorders, 2023, 01-15, Volume: 321 Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Nasal Sprays; Treatment Outcome	2023
Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD. The international journal of neuropsychopharmacology, 2023, 03-22, Volume: 26, Issue:3 Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Hallucinations; Humans; Ketamine; Psychotic Disorders	2023
Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray. Psychiatry research, 2023, Volume: 323 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Nasal Sprays; Treatment Outcome	2023
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2023, Volume: 48, Issue:8 Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Nasal Sprays; Quality of Life; Treatment Outcome	2023
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. The New England journal of medicine, 2023, Oct-05, Volume: 389, Issue:14 Topics: Antidepressive Agents; Delayed-Action Preparations; Depression; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Humans; Ketamine; Nasal Sprays; Quetiapine Fumarate; Recurrence; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Single-Blind Method; Treatment Outcome	2023
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2020, Volume: 28, Issue:2 Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Nasal Sprays; Treatment Outcome	2020
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial. BMC psychiatry, 2019, 11-29, Volume: 19, Issue:1 Topics: Administration, Oral; Adult; Antidepressive Agents; Cost-Benefit Analysis; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Treatment Outcome	2019
Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. Journal of affective disorders, 2020, 03-01, Volume: 264 Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Japan; Ketamine; Treatment Outcome	2020
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data. The international journal of neuropsychopharmacology, 2020, 07-29, Volume: 23, Issue:7 Topics: Administration, Intranasal; Adolescent; Adult; Aged; Algorithms; Antidepressive Agents; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Ketamine; Male; Middle Aged; Patient Compliance; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult	2020
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). The Journal of clinical psychiatry, 2020, 04-28, Volume: 81, Issue:3 Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Cognition; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Middle Aged; Nasal Sprays; Young Adult	2020
Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials. The international journal of neuropsychopharmacology, 2020, 12-03, Volume: 23, Issue:9 Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Dissociative Disorders; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Middle Aged; Nasal Sprays; Outcome Assessment, Health Care; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptors, Opioid, mu	2020
Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE Study. Psychiatry research, 2020, Volume: 293 Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Male; Middle Aged; Prospective Studies; Qualitative Research; Self Report	2020
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression. Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Ketamine; Male; Middle Aged; Nasal Sprays; Prospective Studies; Risk Assessment; Treatment Outcome; Young Adult	2021
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Tr Journal of affective disorders, 2021, 02-15, Volume: 281 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine; Nasal Sprays; Patient Health Questionnaire; Treatment Outcome	2021
Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial. Journal of psychiatric research, 2021, Volume: 138 Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2021
Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study. Psychiatry research, 2021, Volume: 303 Topics: Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine	2021
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies. CNS drugs, 2021, Volume: 35, Issue:7 Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Middle Aged; Nasal Sprays; Nose Diseases; Olfaction Disorders; Olfactometry; Time; Treatment Outcome	2021
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. Depression and anxiety, 2021, Volume: 38, Issue:11 Topics: Adult; Anxiety; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Humans; Ketamine; Treatment Outcome	2021
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA psychiatry, 2018, 02-01, Volume: 75, Issue:2 Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Ketamine; Male; Middle Aged; Treatment Outcome; Young Adult	2018
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. The American journal of psychiatry, 2019, 06-01, Volume: 176, Issue:6 Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Ketamine; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride	2019
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA psychiatry, 2019, 09-01, Volume: 76, Issue:9 Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Middle Aged; Nasal Sprays; Outcome Assessment, Health Care; Remission Induction; Secondary Prevention	2019
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). The international journal of neuropsychopharmacology, 2019, 10-01, Volume: 22, Issue:10 Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Antidepressive Agents; Citalopram; Delayed-Action Preparations; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Ketamine; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult	2019

Other Studies

84 other study(ies) available for esketamine and Depressive Disorder, Treatment-Resistant

Article	Year
Patterns of use, clinical efficacy, safety and tolerability of Ketamine and Esketamine in treatment-resistant depression: Towards registry-based surveillance systems. Journal of affective disorders, 2022, 01-15, Volume: 297 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Registries; Treatment Outcome	2022
Antipanic-like effect of esketamine and buprenorphine in rats exposed to acute hypoxia. Behavioural brain research, 2022, 02-10, Volume: 418 Topics: Analgesics, Opioid; Animals; Anti-Anxiety Agents; Antidepressive Agents; Buprenorphine; Depressive Disorder, Treatment-Resistant; Humans; Hypoxia; Ketamine; Locomotion; Male; Rats; Rats, Wistar	2022
Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report. International clinical psychopharmacology, 2022, 01-01, Volume: 37, Issue:1 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Middle Aged	2022
Recommendations for the Usage of Ketamine and Esketamine. The American journal of psychiatry, 2021, Volume: 178, Issue:12 Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2021
Mechanisms of Action of Ketamine and Esketamine. The American journal of psychiatry, 2021, Volume: 178, Issue:12 Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2021
Ketamine and Esketamine for Treatment-Resistant Depression: Response to Reus, Mattes, and Schatzberg. The American journal of psychiatry, 2021, Volume: 178, Issue:12 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2021
Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti-depressive drug on the market. Fundamental & clinical pharmacology, 2022, Volume: 36, Issue:3 Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine	2022
Efficacy and safety of repeated esketamine intravenous infusion in the treatment of treatment-resistant depression: A case series. Asian journal of psychiatry, 2022, Volume: 68 Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Infusions, Intravenous; Ketamine	2022
How to deprescribe esketamine in resistant depression? A point of view after first clinical uses. Epidemiology and psychiatric sciences, 2022, Jan-11, Volume: 31 Topics: Deprescriptions; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2022
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression. The international journal of neuropsychopharmacology, 2022, 04-19, Volume: 25, Issue:4 Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays; Recurrence; Treatment Outcome	2022
Esketamine: uncertain safety and efficacy data in depression. The British journal of psychiatry : the journal of mental science, 2021, Volume: 219, Issue:5 Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2021
Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2022, Volume: 23, Issue:9 Topics: Antidepressive Agents; Borderline Personality Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Impulsive Behavior; Ketamine; Suicidal Ideation	2022
Is approving esketamine as an antidepressant for treatment resistant depression associated with recreational use and risk perception of ketamine? Results from a longitudinal and cross-sectional survey in nightlife attendees. The International journal on drug policy, 2022, Volume: 102 Topics: Adolescent; Adult; Antidepressive Agents; Cross-Sectional Studies; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Perception; Young Adult	2022
Antidepressant effect of prolonged twice-weekly intranasal esketamine treatments after nonresponse to electroconvulsive therapy in a patient with treatment-resistant depression. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2022, Volume: 34, Issue:1 Topics: Administration, Intranasal; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Humans; Ketamine	2022
Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme. International journal of psychiatry in clinical practice, 2022, Volume: 26, Issue:4 Topics: Administration, Intranasal; Adult; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Male; Middle Aged; Nasal Sprays	2022
Intranasal esketamine for depression: Not so special K. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2022, Volume: 30, Issue:4 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2022
Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting. JAMA psychiatry, 2022, 07-01, Volume: 79, Issue:7 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2022
Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression. Progress in neuro-psychopharmacology & biological psychiatry, 2022, 12-20, Volume: 119 Topics: Bupropion; Depression; Depressive Disorder, Treatment-Resistant; Dopamine; Humans; Ketamine; N-Methylaspartate	2022
Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression. Clinical drug investigation, 2022, Volume: 42, Issue:10 Topics: Administration, Intranasal; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine	2022
Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression. The Journal of clinical psychiatry, 2022, 09-19, Volume: 83, Issue:6 Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dizziness; Humans; Ketamine; Nasal Sprays; Nausea; Vertigo	2022
Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study). Journal of affective disorders, 2022, 12-15, Volume: 319 Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2022
Pros and cons of esketamine treatment in psychiatry. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2022, Volume: 65 Topics: Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Psychiatry	2022
Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice. BMJ open, 2022, 09-01, Volume: 12, Issue:9 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Multicenter Studies as Topic; Observational Studies as Topic; Prospective Studies; Treatment Outcome	2022
Clinical experiences with intranasal esketamine for major depressive disorder resistant to treatment and with a psychiatric emergency: case presentations. International clinical psychopharmacology, 2023, 05-01, Volume: 38, Issue:3 Topics: Administration, Intranasal; Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Male; Middle Aged	2023
Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression. Bipolar disorders, 2023, Volume: 25, Issue:3 Topics: Antidepressive Agents; Bipolar Disorder; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2023
Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series. The Journal of clinical psychiatry, 2023, 02-01, Volume: 84, Issue:2 Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2023
Reconsidering "dissociation" as a predictor of antidepressant efficacy for esketamine. Psychopharmacology, 2023, Volume: 240, Issue:4 Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine; Treatment Outcome	2023
The parable of the Therapeutic Goods Administration approval of esketamine (Spravato) in Australia. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2023, Volume: 31, Issue:2 Topics: Australia; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2023
Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2023, Volume: 74 Topics: Administration, Intranasal; Adult; Antidepressive Agents; Comorbidity; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug-Related Side Effects and Adverse Reactions; Humans; Ketamine; Retrospective Studies; Substance-Related Disorders	2023
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study. Psychopharmacology, 2023, Volume: 240, Issue:7 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Patient Outcome Assessment	2023
Giovanni Martinotti: Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine and bipolar × unipolar treatment resistant depression. Bipolar disorders, 2023, Volume: 25, Issue:5 Topics: Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2023
Reduction in Cognitive Symptoms Following Intranasal Esketamine Administration in Patients With Chronic Treatment-resistant Depression: A 12-Week Case Series. Journal of psychiatric practice, 2023, Jul-01, Volume: 29, Issue:4 Topics: Antidepressive Agents; Cognition; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans	2023
Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance. Current medical research and opinion, 2023, Volume: 39, Issue:8 Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Female; Humans; Insurance; Male; Middle Aged; Nasal Sprays	2023
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. CNS drugs, 2023, Volume: 37, Issue:8 Topics: Adolescent; Adult; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Middle Aged; Nasal Sprays; Treatment Outcome; Young Adult	2023
Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING). Psychiatry research, 2023, Volume: 327 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Machine Learning; Reproducibility of Results; Retrospective Studies; Treatment Outcome	2023
Esketamine for resistant depression in older people with cognitive impairment: A case report. L'Encephale, 2023, Volume: 49, Issue:6 Topics: Aged; Antidepressive Agents; Cognitive Dysfunction; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2023
Exploring the potential of a bridge therapy: Synergistic approach integrating intravenous ketamine and intranasal esketamine for treatment-resistant depression. Acta psychiatrica Scandinavica, 2023, Volume: 148, Issue:4 Topics: Bridge Therapy; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2023
Early effects predict trajectories of response to esketamine in treatment-resistant depression. Journal of affective disorders, 2023, 12-01, Volume: 342 Topics: Administration, Intranasal; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Longitudinal Studies; Treatment Outcome	2023
Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of ASPIRE I (a randomized, double-blind, placeb Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2023, Volume: 15, Issue:4 Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Nasal Sprays; Standard of Care; Suicidal Ideation; Treatment Outcome	2023
Esketamine More Effective Than Quetiapine for Hard-to-Treat Depression. JAMA, 2023, 11-07, Volume: 330, Issue:17 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Quetiapine Fumarate; Treatment Outcome	2023
Establishing an esketamine clinic in Australia: Practical recommendations and clinical guidance from an expert panel. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2023, Volume: 15, Issue:4 Topics: Antidepressive Agents; Australia; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Quality of Life	2023
Comment on a Word to the Wise About Intranasal Esketamine. The American journal of psychiatry, 2019, 10-01, Volume: 176, Issue:10 Topics: Administration, Intranasal; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2019
More Thoughts on Intranasal Esketamine: Response to Drevets et al. The American journal of psychiatry, 2019, 10-01, Volume: 176, Issue:10 Topics: Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2019
US Food and Drug Administration approval of esketamine and brexanolone. The lancet. Psychiatry, 2019, Volume: 6, Issue:12 Topics: Antidepressive Agents; beta-Cyclodextrins; Depression, Postpartum; Depressive Disorder, Treatment-Resistant; Drug Combinations; Female; Humans; Ketamine; Pregnanolone; United States; United States Food and Drug Administration	2019
Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. The lancet. Psychiatry, 2019, Volume: 6, Issue:12 Topics: Clinical Trials as Topic; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Treatment Outcome; United States; United States Food and Drug Administration	2019
The Efficacy and Safety of Esketamine for the Treatment-Resistant Depression in Older Adults: Comments on TRANSFORM-3 Trial Results. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2020, Volume: 28, Issue:2 Topics: Aged; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays	2020
[How we see the development of clinical trials from the investigators' side?] Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata, 2019, Volume: 34, Issue:4 Topics: Clinical Trials as Topic; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays; Outsourced Services; Psychiatry; Research Personnel	2019
Esketamine for treatment resistant depression: a trick of smoke and mirrors? Epidemiology and psychiatric sciences, 2019, Dec-16, Volume: 29 Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Drug Approval; Evidence-Based Medicine; Humans; Infusions, Intravenous; Ketamine; United States; United States Food and Drug Administration	2019
The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression. Journal of managed care & specialty pharmacy, 2020, Volume: 26, Issue:1 Topics: Administration, Intranasal; Adolescent; Adult; Aerosols; Affect; Aged; Antidepressive Agents; Comparative Effectiveness Research; Cost-Benefit Analysis; Depressive Disorder, Treatment-Resistant; Drug Costs; Evidence-Based Medicine; Female; Humans; Ketamine; Male; Middle Aged; Patient Safety; Policy Making; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult	2020
Dissociating the Clinical Role and Economic Value of Intranasal Esketamine. Journal of managed care & specialty pharmacy, 2020, Volume: 26, Issue:1 Topics: Administration, Intranasal; Aerosols; Affect; Antidepressive Agents; Cost-Benefit Analysis; Depressive Disorder, Treatment-Resistant; Drug Costs; Evidence-Based Medicine; Humans; Ketamine; Patient Safety; Randomized Controlled Trials as Topic; Treatment Outcome	2020
Esketamine as a treatment for paediatric depression: questions of safety and efficacy. The lancet. Psychiatry, 2020, Volume: 7, Issue:10 Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2020
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program. CNS drugs, 2020, Volume: 34, Issue:3 Topics: Administration, Intranasal; Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Heart; Humans; Ketamine; Male; Middle Aged; Nasal Sprays; Young Adult	2020
Approval of esketamine for treatment-resistant depression. The lancet. Psychiatry, 2020, Volume: 7, Issue:3 Topics: beta-Cyclodextrins; Depression; Depressive Disorder, Treatment-Resistant; Drug Combinations; Humans; Ketamine; Pregnanolone; United States; United States Food and Drug Administration	2020
Approval of esketamine for treatment-resistant depression - Authors' reply. The lancet. Psychiatry, 2020, Volume: 7, Issue:3 Topics: Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2020
Approval of esketamine for treatment-resistant depression - Author's reply. The lancet. Psychiatry, 2020, Volume: 7, Issue:3 Topics: Depression; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Pregnancy; Suicide, Attempted	2020
A New Rapid-Acting Antidepressant. Cell, 2020, 04-02, Volume: 181, Issue:1 Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Drug Approval; GABAergic Neurons; Humans; Ketamine; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate	2020
Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui. Epidemiology and psychiatric sciences, 2020, 04-29, Volume: 29 Topics: Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2020
Esketamine clinical trials: reply to Maju Epidemiology and psychiatric sciences, 2020, Apr-29, Volume: 29 Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Drug and Narcotic Control; Drug Approval; Evidence-Based Medicine; Humans; Ketamine; United States; United States Food and Drug Administration	2020
Esketamine Nasal Spray for Treatment-Resistant Depression. Nursing for women's health, 2020, Volume: 24, Issue:3 Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Male; Nasal Sprays; Quality of Health Care; United States	2020
Response to a recently published systematic review on intranasal esketamine for major depressive disorder. Journal of affective disorders, 2020, 08-01, Volume: 273 Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine	2020
Long-term treatment of depression with intranasal esketamine: Is it justified? Asian journal of psychiatry, 2020, Volume: 54 Topics: Administration, Intranasal; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2020
Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression. Journal of psychopharmacology (Oxford, England), 2020, Volume: 34, Issue:10 Topics: Adult; Antidepressive Agents; Blood Pressure; Cohort Studies; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Monitoring; Female; Heart Rate; Humans; Hypertension; Injections, Subcutaneous; Ketamine; Male; Middle Aged; Retrospective Studies	2020
Three Months of Treatment With Esketamine: Effects on Depression, Insomnia, and Weight. The primary care companion for CNS disorders, 2020, 07-09, Volume: 22, Issue:4 Topics: Administration, Intranasal; Antidepressive Agents; Body Weight; Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Middle Aged; Sleep Initiation and Maintenance Disorders; Time Factors	2020
Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies - Authors' reply. Journal of affective disorders, 2020, 09-01, Volume: 274 Topics: Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine	2020
A new indication for esketamine nasal spray (Spravato). The Medical letter on drugs and therapeutics, 2020, Sep-21, Volume: 62, Issue:1607 Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays; Suicidal Ideation	2020
Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2021, Volume: 22, Issue:6 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays	2021
Esketamine for Postpartum Suicidality. Biological psychiatry, 2021, 03-15, Volume: 89, Issue:6 Topics: Depressive Disorder, Treatment-Resistant; Female; Humans; Ketamine; Postpartum Period; Suicide	2021
Combination of Electroconvulsive Therapy Alternating With Intravenous Esketamine Can Lead to Rapid Remission of Treatment Resistant Depression. The journal of ECT, 2021, 06-01, Volume: 37, Issue:2 Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Humans; Ketamine	2021
Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse? Journal of affective disorders, 2021, 03-01, Volume: 282 Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2021
Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity. Journal of psychopharmacology (Oxford, England), 2021, Volume: 35, Issue:2 Topics: Adult; Antidepressive Agents; Anxiety; Anxiety Disorders; Comorbidity; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Ketamine; Male; Retrospective Studies	2021
At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study. Depression and anxiety, 2021, Volume: 38, Issue:5 Topics: Antidepressive Agents; Cost of Illness; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Retrospective Studies	2021
Oral S-ketamine effective after deep brain stimulation in severe treatment-resistant depression and extensive comorbidities. BMJ case reports, 2021, Jan-25, Volume: 14, Issue:1 Topics: Administration, Oral; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Clozapine; Deep Brain Stimulation; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Female; Glycopyrrolate; Hallucinations; Humans; Ketamine; Middle Aged; Muscarinic Antagonists; Nitrazepam; Obsessive-Compulsive Disorder; Treatment Failure; Venlafaxine Hydrochloride	2021
Comments to Drs. Bahji, Vazquez, and Zarate. Journal of affective disorders, 2021, 03-15, Volume: 283 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2021
Letter to the editor - Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Journal of affective disorders, 2021, 03-15, Volume: 283 Topics: Adult; Depression; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Ketamine; Random Allocation	2021
Letter to the Editor: Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Journal of affective disorders, 2021, 06-15, Volume: 289 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2021
Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study. CNS drugs, 2021, Volume: 35, Issue:8 Topics: Administration, Intravenous; Adult; Aged; Antidepressive Agents; Blood Pressure; Cohort Studies; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Interactions; Female; Heart Rate; Humans; Injections, Subcutaneous; Ketamine; Male; Middle Aged; Monoamine Oxidase Inhibitors; Retrospective Studies; Tranylcypromine; Young Adult	2021
Which are the demographic and clinical characteristics of patients who respond to subcutaneous esketamine? Journal of psychopharmacology (Oxford, England), 2021, Volume: 35, Issue:12 Topics: Demography; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2021
Which are the demographic and clinical characteristics of patients who respond to subcutaneous esketamine? Journal of psychopharmacology (Oxford, England), 2021, Volume: 35, Issue:12 Topics: Demography; Depressive Disorder, Treatment-Resistant; Humans; Ketamine	2021
Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression. Journal of psychiatric research, 2019, Volume: 111 Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Ketamine; Male; Middle Aged; Nasal Sprays; Outcome and Process Assessment, Health Care; Pilot Projects; Placebo Effect; Placebos; Predictive Value of Tests; Psychiatric Status Rating Scales; Young Adult	2019
Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine. Pharmacology, biochemistry, and behavior, 2019, Volume: 181 Topics: Administration, Intranasal; Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Dose-Response Relationship, Drug; Ketamine; Locomotion; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Prepulse Inhibition; Receptors, N-Methyl-D-Aspartate; Saline Solution; Stress, Psychological	2019
Esketamine nasal spray (Spravato) for treatment-resistant depression. The Medical letter on drugs and therapeutics, 2019, Apr-08, Volume: 61, Issue:1569 Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays; Receptors, N-Methyl-D-Aspartate; Stereoisomerism	2019
Esketamine and rapastinel, but not imipramine, have antidepressant-like effect in a treatment-resistant animal model of depression. Acta neuropsychiatrica, 2019, Volume: 31, Issue:5 Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Imipramine; Ketamine; Male; Oligopeptides; Rats; Rats, Sprague-Dawley; Swimming; Treatment Outcome	2019
New Nasal Spray for Treatment-Resistant Depression. The American journal of nursing, 2019, Volume: 119, Issue:7 Topics: Administration, Intranasal; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays	2019
Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression. Acta psychiatrica Scandinavica, 2019, Volume: 140, Issue:2 Topics: Administration, Intranasal; Anesthetics, Dissociative; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate; Risk Factors; Substance-Related Disorders; Suicidal Ideation; United States; United States Food and Drug Administration	2019